Paper card · curated
Human cannabinoid pharmacokinetics
Huestis MA
Chemistry & Biodiversity · 2007
Abstract excerpt
Comprehensive review of human pharmacokinetics for THC and metabolites across inhalation, oral, sublingual, and intravenous routes. Documents first-pass hepatic metabolism converting THC to 11-hydroxy-THC (~2-3× the CB1 affinity of parent THC), variable oral bioavailability (6-19%), and the dose-stacking risk inherent to oral cannabis. Reviews CBD pharmacokinetics including the inverted-U dose-response in some clinical contexts.
Excerpt from the published abstract. Full paper at the journal link below.
Joe's notes
How to read this paper
If you're interested in why edibles act differently than inhalation, this is the citation. The 11-OH-THC story is well-documented here — it explains the longer onset, the higher peak intensity, and the reason dose-stacking is dangerous with edibles.
Read the paper
No DOI or external link on file for this entry. Search the title in Google Scholar or PubMed for the full paper.
FDA disclaimer
Research papers in this library describe published scientific findings. They are not therapeutic claims. These statements have not been evaluated by the FDA. Compounds discussed in any paper are not intended to diagnose, treat, cure, or prevent any disease. Talk to a healthcare provider before making decisions about supplements.